The first stop for professional medicines advice

Terbinafine

Published
Topics: CCG commissioned new medicinesInfection and infectious diseasesNew Medicines · Patent expiriesPre-registration new medicines (UK/EU)Safety in BreastfeedingSkin disordersStability in dosette boxesTerbinafine ·
Contents
  1. dm+d
  2. Medicine Compliance Aid Stability
    1. Lamisil · Novartis Pharmaceuticals UK Ltd
  3. Lactation Safety Information
    1. Oral
    2. For topical use

dm+d

108925005

Medicine Compliance Aid Stability

LamisilNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Lamisil
Tablets 250mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from light.
4 November 2022
Usage of Medicines in Compliance Aids

Lactation Safety Information

Oral

Oral
Caution
Fluconazole
Limited published evidence of safety
Doses of 500mg daily have produced low levels in milk
Monitor infant for jaundice and other signs of liver toxicity
Monitor infant for gastro-intestinal disturbances, especially if used for prolonged periods or in high doses, although unlikely to occur.
10 November 2020
LactMed

For topical use

For topical use
Yes
Safety in Lactation: Antifungal skin preparations
17 September 2020